An E7-based therapeutic vaccine protects mice against HPV16 associated cancer

Aldo Venuti, Silvia Massa, Vadim Mett, Laura Dalla Vedova, Francesca Paolini, Rosella Franconi, Vidadi Yusibov

Research output: Contribution to journalArticle


Plant-derived vaccines represent an attractive strategy for cancer immunotherapy due to their relative safety and cost-effectiveness. We evaluated the anti-tumour activity of a Nicotiana benthamiana produced vaccine candidate based on the non-transforming E7 protein of HPV-16 fused to β-1,3-1,4-glucanase of Clostridium thermocellum. Two doses of vaccine at two week intervals were administered to groups of C57BL/6 mice starting 3 or 6 days after challenge with tumourigenic E7-expressing TC-1* cells. Inhibition of tumour growth and increased survival was observed in both groups treated with vaccine. These data suggest the potential of plants as a platform for producing therapeutic vaccines.

Original languageEnglish
Pages (from-to)3395-3397
Number of pages3
Issue number25-26
Publication statusPublished - May 26 2009



  • Cancer vaccine
  • Human papilloma virus
  • Plant-produced vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Venuti, A., Massa, S., Mett, V., Vedova, L. D., Paolini, F., Franconi, R., & Yusibov, V. (2009). An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine, 27(25-26), 3395-3397.